Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-T1 phase I trial of TAH-1005 ([211At] sodium astatide) in differentiated thyroid cancer
jRCT2051210144Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label trial of sodium astatide (211At) in well-differentiated thyroid cancer (WDTC) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Adverse events and Dose-limiting toxicity. Started Dec 2021; status: completed.
02
Drugs
sodium astatide (211At)
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on jRCT2051210144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210144.